Agios Pharmaceuticals, Inc.

247 articles with Agios Pharmaceuticals, Inc.

• Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

  10/29/2020

  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a webinar focused on its pyruvate kinase-R (PKR) activation clinical programs and the commercial outlook across three distinct hemolytic anemias on Thursday, November 19, 2020 from 8:00 a.m. to 10:30 a.m. ET.

• Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020

  10/22/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.

• Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

  10/16/2020

  – Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

• Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

  9/21/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced the results of the final overall survival analysis from its global Phase 3 ClarIDHy trial of TIBSOVO® in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation.

• 

  BioSpace Movers & Shakers, Sept. 11

  9/11/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.

• Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate AffairsAndrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020  

  9/8/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced the appointment of Jonathan Biller to the role of chief financial officer, head of legal and corporate affairs effective September 11, 2020.

• Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

  8/27/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 at 9:50 a.m. ET.

• Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

  8/6/2020

  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com.

• Agios Reports Business Highlights and Second Quarter 2020 Financial Results

  7/30/2020

  Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million

• Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

  7/16/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m.

• Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

  6/17/2020

  Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 9:00 a.m. ET.

• Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study

  6/12/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α- and β-thalassemia.

• Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

  6/12/2020

  Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency or Expected in the Context of Sickle Cell Disease

• Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

  6/12/2020

  Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments

• Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals

  6/9/2020

  Agreement calls for identifying IDH gene mutations using Oncomine Precision Assay and the Ion Torrent Genexus System, a new turnkey, next-generation sequencing solution   [09-June-2020]   CARLSBAD, Calif. , June 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-develo

• Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

  5/29/2020

  Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months

• Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

  5/19/2020

  TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma

• Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

  5/14/2020

  – Data Supporting Utility of TIBSOVO ® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET –

• Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

  5/13/2020

  Agios Pharmaceuticals, Inc. announced that vorasidenib and ivosidenib clinical data will be presented at the American Society of Clinical Oncology Annual Meeting being held virtually May 29-31, 2020.

• Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

  5/12/2020

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 3:40 p.m. ET.